A study shows that Romanian patients wait, on average, 460 days for access to innovative medicines, seriously affecting critical areas such as oncology.
Andreea Lificiu
Health
https://www.pexels.com/
Always see our news on Google
An analysis carried out by Novartis Romania highlights the long delays in Romanian patients' access to innovative medicines, with an average of 460 days from the approval of compensation by the ANMDM. Oncology is the most affected, with 40% of the indications analyzed. Although the assessment process has improved, the compensation steps remain lengthy. The study emphasizes the need for reforms in the reimbursement system to ensure rapid and equitable access to treatment.
Sources
Studiu: Pacienţii români aşteaptă, în medie, 460 de zile ca să primească medicamentele inovatoare compensate/ Aproximativ 40% din totalul indicaţiilor terapeutice analizate au fost de natură oncologică
Studiu: Pacienţii români aşteaptă, în medie, 460 de zile ca să primească medicamentele inovatoare compensate / Aproximativ 40% din totalul indicaţiilor terapeutice analizate au fost de natură oncologică
Studiu: Pacienţii români aşteaptă, în medie, 460 de zile ca să primească medicamentele inovatoare compensate / Aproximativ 40% din totalul indicaţiilor terapeutice analizate au fost de natură oncologică
Latest News
23:00
NASA has published images of the crater formed on the Moon after the Falcon 9 rocket stage crashed on August 5.
22:53
ECB: Europe cannot afford to miss the opportunities offered by artificial intelligence
22:49
Energy consumption is on the rise. When is the peak consumption expected this year?
22:45
The assessment of the buildings affected by the explosion in Rahova has begun. The operation will conclude on September 9.
22:35
Bogdan Ivan responds to Ilie Bolojan, asking him to confirm that large energy consumers will not be affected by power cuts.
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
